CDXC ChromaDex Corp. Operating Margin

Key patents for the Niagen molecule create a powerful barrier to entry for competitors, which is reflected in the operating margin chart on GURU.Markets, where the current level is approximately 10.60. ChromaDex Corporation (CDXC) generates revenue through B2B licensing of raw materials, thereby minimizing logistics costs. The development of the Tru Niagen brand and partnerships with institutes enable the effective commercialization of cellular aging science.
ChromaDex Corp. - analytical breakdowns and key metrics (CDXC)

The strategic alliance between ChromaDex Corporation (CDXC) and Nestle Health Science to promote Niagen enables cost optimization, directly impacting profit generation efficiency. This metric is calculated as the ratio of operating income to revenue, reflecting the portion of funds remaining after all production costs are paid, which establishes the operating margin as a key indicator of pricing power and business scalability.